ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,477.90
0.00%
Dow Jones
39,127.80
0.00%
US Dollar vs MXN
18.3766
0.33%
Brent Oil
84.955
0.57%
Bitcoin
61,141.63
0.54%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. USOTC
  6. Daiichi Sankyo Company Ltd (PK) (DSNKY)

  7. Daiichi Sankyo Company Ltd (PK) (DSNKY) Noticias

DSNKY

Daiichi Sankyo (PK) (DSNKY)

Daiichi Sankyo Company Ltd (PK)
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:USOTC:DSNKY
FechaHoraFuenteTítuloSímboloCompañía
23/10/202301:49Dow Jones NewsAstraZeneca, Daiichi Sankyo's Enhertu Gets Approval in EU For Lung Cancer TreatmentUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
19/10/202319:30Dow Jones NewsMerck, Daiichi Sankyo Ink Commercialization Deal for Up to $22 BillionUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
22/09/202301:53Dow Jones NewsAstraZeneca Says Trial Results For Breast Cancer Drug Were Highly PositiveUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
15/09/202309:51Dow Jones NewsAstraZeneca's Lung-Cancer Treatment Gets Recommended for Approval in the EUUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
11/09/202301:55Dow Jones NewsAstraZeneca Says Datopotamab Deruxtecan Combined With Imfinzi Shows High Disease Control RatesUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
03/07/202301:50Dow Jones NewsAstraZeneca Says Datopotamab Deruxtecan Phase 3 Trial Shows Positive Results in Lung Cancer PatientsUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
05/06/202307:53Dow Jones NewsAstraZeneca Cancer Drug Enhertu Shows Clinically Meaningful, Durable Response in TrialUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
14/11/202201:52Dow Jones NewsAstraZeneca Says Enhertu Recommended for EU Approval for Gastric CancerUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
12/08/202201:53Dow Jones NewsAstraZeneca, Daiichi's Enhertu Approved by the FDA for Lung Cancer TreatmentUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
09/08/202205:49Dow Jones NewsAstraZeneca Reports Promising Data From Lung Cancer TrialUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
27/06/202201:55Dow Jones NewsAstraZeneca Enhertu Breast Cancer Drug Is Recommended for EU ApprovalUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
05/05/202202:03Dow Jones NewsAstraZeneca's Enhertu Approved in US for Metastatic Breast Cancer TreatmentUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
19/04/202201:55Dow Jones NewsAstraZeneca, Daiichi Sankyo Say FDA Has Accepted Enhertu for Priority ReviewUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
21/02/202203:38Dow Jones NewsAstraZeneca, Daiichi Sankyo Report Positive Trial Results for Enhertu Breast-Cancer Treatment -- UpdateUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
17/01/202201:54Dow Jones NewsAstraZeneca's Enhertu Granted Priority Review by US RegulatorUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
17/09/202112:05Dow Jones NewsAstraZeneca Sees Positive Results for Enhertu TrialUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
30/03/201902:02Dow Jones NewsCancer Drug Deal Carries High Price -- WSJUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
28/07/201607:10Dow Jones NewsChina's Fosun Close to Deal for India's Gland PharmaUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
20/04/201517:00Dow Jones NewsDaiichi Sankyo to Sell Sun Pharma StakeUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
23/03/201516:44The Motley FoolThis Market Could Grow 6250% in 10 YearsUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
02/12/201414:38Dow Jones NewsAbilify Maker Otsuka to Buy Avanir for $3.5 BillionUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
23/01/201419:12Dow Jones NewsFDA Bars Ingredients From Ranbaxy's India PlantUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
17/09/201305:43Dow Jones NewsASIA MARKETS: China Leads Asia Stocks LowerUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
17/09/201301:03Dow Jones NewsASIA MARKETS: Asia Stocks Mostly Lower Ahead Of Fed MeetingUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
02/09/201303:35Dow Jones NewsASIA MARKETS: Hong Kong Stocks Jump To Lead Broad Asia GainsUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
01/09/201320:28Dow Jones NewsASIA MARKETS: Asia Stocks Rise After Official China Factory DataUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
24/04/201305:50Dow Jones NewsNovartis Boosted by Drug LaunchesUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
22/02/201311:20Dow Jones NewsRanbaxy Resumes Generic Lipitor Production for U.S.USOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
02/10/201212:01Dow Jones NewsArQule, Daiichi Sankyo End Lung-Cancer TrialUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
27/08/201207:04Dow Jones NewsLilly/Daiichi Blood Thinner Misses Mark in Head-to-Head Study Vs PlavixUSOTC:DSNKYDaiichi Sankyo Company Ltd (PK)
 Showing the most relevant articles for your search:USOTC:DSNKY

Su Consulta Reciente

NYSE
DIS
Walt Disney
FX
EURUSD
Euro vs US Dollar
NYSE
BAC
Bank of America
NASDAQ
MSFT
Microsoft
AMEX
SPY
SPDR S&P 500
NASDAQ
GOOGL
Alphabet
NYSE
VZ
Verizon Communications
PM
XAUUSD
Gold vs US Dollar
NASDAQ
AAPL
Apple
NYSE
JPM
JP Morgan Chase
NYSE
NKE
Nike
NYSE
XOM
Exxon Mobil
USI
USTECH100
US Tech 100
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NASDAQ
NVDA
NVIDIA
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados